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Objective: It has been assumed that the need for homograft replacement is due to
somatic outgrowth, but this has not been adequately studied. Our objective was to
identify reasons for homograft conduit failure.
Methods: The records and imaging studies of 40 patients undergoing homograft
conduit replacement of the right ventricular outflow tract from 1996 to 2000 were
retrospectively reviewed.
Results: The majority of patients had a diagnosis of tetralogy of Fallot (n  20) and
truncus arteriosus (n  13). The median age at the initial operation was 8 months
(0.25–108 months). The initial homograft sizes ranged from 9 to 22 mm, and 28
conduits were of pulmonary origin. When comparing size of the initial homograft
with patients’ expected pulmonary valve diameter (z  0), oversizing was noted to
be3 (range, 0.83–5.4). Median interval to conduit failure was 5.3 years (0.83–11.3
years). At homograft replacement, only 12 patients had an existing conduit that was
1 SD below the homograft conduit size needed (z  1). Most conduits had
important regurgitation, but this was rarely a primary reason for reintervention (n 
1). Reoperation was usually required for stenosis, with a median gradient of 53 mm
Hg (20–140 mm Hg). Stenosis was further categorized angiographically as follows:
homograft valvular stenosis (shrinkage; 21/40 [53%]), distal anastomotic stenosis
(4/40 [10%]), conduit kinking (3/40 [8%]), sternal compression (3/40 [8%]), pos-
terior shelf impingement (2/40 [5%]), and somatic outgrowth (3/40 [8%]). Replace-
ment in 2 patients was for proximal hood aneurysm. Several patients (7/40 [18%])
had stenosis at multiple levels. The average decrease in conduit diameter was 47%
(28%-73%).
Conclusions: Somatic outgrowth is seldom a primary reason for homograft conduit
replacement of the right ventricular outflow tract. The most common cause for
failure is conduit obstruction with thickening and shrinkage at the annular area.
Conduit stenosis was responsible for failure in 53% of patients, technical issues
were responsible for 30%, and only 8% failed as a result of somatic outgrowth.
Placement of a smaller homograft (z  0) at the initial operation may decrease
the incidence of conduit kinking, sternal compression, and posterior shelf impinge-
ment.
Anumber of studies have documented the durability of homograftsused for right ventricular outflow tract (RVOT) reconstruction.1-8Although risk factors for conduit replacement have been de-scribed, little attention has been given to the exact mechanisms ofconduit failure. The potential role of the immune system in thedeterioration of homografts has also been increasingly ex-
plored,9-18 and this appears to be one logical explanation for the variability in
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conduit survival. To explore what factors may be contrib-
uting to homograft failure, we have reviewed our conduit
replacement experience over the past 4 years.
Methods
A retrospective review of all patients undergoing RVOT ho-
mograft conduit replacement between 1996 and 2000 was carried
out.
Demographics at the Prior Conduit Placement
Among the 40 study patients, the median age at prior conduit
placement was 8 months (0.25–108 months), the weight was 6.7 kg
(2.7–26.1 kg), and the body surface area (BSA) was 0.36 m2
(0.18–0.97 m2). The most common congenital heart defects in the
group were tetralogy of Fallot (with or without pulmonary atresia,
n 20) and truncus arteriosus (n 13). Table 1 lists the anatomic
diagnosis for the entire group.
Prior Homograft Procedure
At the prior operation, 28 (70%) of the 40 patients had a pulmo-
nary homograft, and 12 had an aortic homograft. The average size
of the prior conduit was 14 mm (9–21 mm). Figure 1 shows the
distribution of the sizes of the prior homograft. The z value
indexed to the patients’ BSA at the prior implant was 3 (0.83–
5.4). Figure 2 shows the distribution of z values for the homografts
implanted at the prior operation. No attempt was made to match
the donor and recipient for blood type. The technique of homograft
placement at the prior operation could be determined in 37 of the
40 patients. In 17 patients the proximal anastomosis left the con-
duit in an extracardiac position, with the posterior half of the
homograft anulus sutured to the epicardial aspect of the right
ventriculotomy augmented by a hood of pericardium or homograft
to complete the connection. The remainder had a more orthotopic
or in situ proximal anastomosis where the posterior homograft
anulus was sutured to the infundibular septum, and the entire
connection was completed to the right ventriculotomy without an
augmenting hood.
Assesment Before Conduit Replacement
After the initial conduit procedure, all patients were followed up
by their cardiologist with serial echocardiography. When nonin-
vasive testing showed evidence of important homograft dysfunc-
tion, cardiac catheterization was performed. In general, the indi-
cations for conduit replacement were a peak gradient across the
RVOT of 50 mm Hg or greater or a right ventricular (RV) pressure
of 75% or greater when compared with systemic pressure. In
addition, severe pulmonary insufficiency leading to RV dilation
and failure was occasionally an indication, as was aneurysmal
dilation of the RV outflow in the region of the proximal conduit
connection.
The prereplacement catheterization and angiography studies were
independently reviewed by two of the authors, one of whom was a
pediatric cardiologist. A consensus was then reached regarding the
mechanism of conduit failure. When there was stenosis of the ho-
mograft, the cause of the obstruction was subcategorized as follows.
Conduit contracture or shrinkage. Conduit contracture or
shrinkage (Figure 3) was characterized by concentric narrowing of
the conduit lumen without evidence of important distortion or
compression. The narrowing was usually at the annular area of the
homograft but could extend more distally to include a part of or the
entire tubular portion as well.
Conduit kinking. A sharp bend leading to distortion of the
conduit was considered to be conduit kinking (Figure 4). This
problem appeared to result from a combination of an extracardiac
positioning of the homograft coupled with a more posterior lie of
the pulmonary confluence. Excess length of the homograft might
also contribute to this problem.
Sternal compression. Flattening of the conduit, particularly in
the region of the proximal anastomosis, was occasionally attrib-
uted to sternal compression (Figure 5). Contributing factors could
include a narrow anterior-posterior dimension of the chest cavity,
dextrorotation of the heart (bringing the conduit under the ster-
num), or anatomic subtypes, such as corrected transposition of the
great arteries (L-TGA) with RVOT obstruction, requiring the con-
TABLE 1. Diagnoses of patients undergoing conduit
replacement
Tetralogy of Fallot with or without pulmonary atresia 20
Truncus arteriosus 13
Pulmonary atresia with IVS 2
Ross procedure 2
TGA with pulmonary stenosis 2
Double-outlet right ventricle 1
IVS, Intact ventricular septum; TGA, transposition of the great arteries.
Figure 1. Distribution of initial conduit size.
Figure 2. Z values for the homografts at initial placement.
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duit to be placed to the right of the ascending aorta. Conduit
oversizing was also thought to be a potential contributing factor to
this problem.
Posterior muscle shelf impingement. This problem was char-
acterized by a posterior indentation just distal to the homograft
valve (Figure 6). This represents RV muscle mass, which lies
between the right ventriculotomy and the pulmonary artery. Pull-
ing the proximal anastomosis down into the RVOT to accomplish
a more in situ or orthotopic positioning of the conduit may increase
the likelihood of this problem.
Figure 3. Angiographic image of a patient with conduit contracture (lateral projection).
Figure 4. Angiographic image of a patient with conduit kinking (lateral projection).
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Distal anastomotic stenosis. When the gradient was clearly at
the distal suture line, the problem was labeled as distal anastomotic
stenosis.
Virtually all of the conduits had some degree of homograft
valve insufficiency, although this was seldom the controlling factor
in the decision to replace the valve. Insufficiency was graded as
mild, moderate, or severe on the basis of both echocardiographic
and angiographic data.
Demographics at Conduit Replacement
Age at conduit replacement was 7.8 years (1.3–16 years), weight
was 21.1 kg (9–67 kg), and BSA was 0.87 m2 (0.45–1.8 m2).
Technique of Conduit Replacement
The replacement operation was through a resternotomy in all but
one patient who, because of multiple previous midline sternoto-
mies and evidence of conduit-sternal continuity, had a clamshell
approach. In 3 of the 39 resternotomies, femoral cannulation was
required because of conduit erosion into the sternum with bleeding
problems on re-entry. For most cases, the majority of the old
homograft tissue was completely resected, and the new conduit or
monocusp was placed into the previous site. In 36 patients the
replacement conduit was a cryopreserved pulmonary homograft.
The remaining 4 patients had a monocusp fashioned from pulmo-
nary homograft tissue. No augmentation hoods were needed. One
patient who had 2 prior homograft failures from sternal compres-
sion caused by an unfavorable anatomic lie had the new conduit
rerouted from the apex of the pulmonary ventricle around the right
border of the heart up to the right pulmonary artery.
The median size of the conduits used for replacement was 21
mm (13–27 mm). The z value of the new homograft pulmonary
anulus was 5 (2.5–8.3).
Results
There were no hospital deaths among the 40 patients un-
dergoing conduit replacement. Important complications in-
cluded 1 patient with a right diaphragm paresis and one
patient who was reoperated on for closure of a fistula
between the right pulmonary artery and the superior pulmo-
nary vein discovered after conduit replacement. The median
hospital stay was 3 days (2–10 days).
Indications for Conduit Replacement
The most common indication for conduit replacement was
stenosis, which was present in 37 (96%) of the 40 patients.
Other infrequent primary indications were RVOT aneurysm
formation in 2 (5%) patients and conduit insufficiency in 1
(3%) patient. The average time to conduit failure in this
series was 5.3 years (0.83–11.3 years). The peak systolic
gradient across the RVOT before conduit replacement was
52.5 mm Hg (20–140 mm Hg), as measured during cathe-
terization. This value was slightly lower than the average
gradient measured by means of echocardiography, which
was 59 mm Hg (12–100 mm Hg). All of the conduits
scheduled for replacement had some degree of homograft
valve insufficiency. This was graded as mild in 17 and
moderate in 14, and the remaining 6 were believed to have
severe regurgitation.
Mechanisms of Conduit Stenosis
When stenosis was the primary indication for conduit re-
placement, the median decrease in conduit diameter was
Figure 5. Angiographic image of a patient with sternal compression (lateral projection).
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47.4% (28%-73%) when compared with the annular size at
the time of implantation. The diameter of the stenotic ho-
mografts averaged 7.6 mm (4.8–12 mm). The primary
mechanism of stenosis was categorized into subsets includ-
ing homograft valvular and perivalvular contracture or
shrinkage (21 [53%]), conduit kinking (4 [10%]), distal
anastomotic stenosis (4 [10%]), sternal compression (3
[8%]), and posterior shelf impingement (2 [5%]). In 3 (8%)
cases the patient appeared to have outgrown an otherwise
well-functioning homograft. Table 2 depicts the incidence
of these subgroups. In these somatic outgrowth cases, the z
value for the conduit valve was greater than –2, indicating
a valve diameter that would be expected to be obstructive.
There were multiple levels of conduit stenosis in 7 (18%) of
the 40 patients.
Z Values at the Time of Replacement
The patient’s normal expected size for the pulmonary valve
at the time of reoperation was compared with the size of the
homograft placed at the prior operation. The z value for the
failed conduits was thus determined. On the basis of this
analysis, only 3 patients had a conduit that was more than 2
SDs (z2) below normal, and in only 21 patients was the
valve to be replaced smaller than normal (z  0). This
information is summarized in Figure 4.
Histology of the Explanted Homograft Tissue
The most consistent histiologic finding among conduits re-
moved for contracture was fibrointimal proliferation with nar-
rowing of the lumen. These findings may be associated with a
response to mechanical injury resulting from flow turbulence,
a manifestation of chronic rejection to the graft, or both.
Figure 6. Angiographic image of a patient with posterior muscle shelf impingement (lateral projection).
Figure 7. Z value of the initial homograft anulus indexed to BSA
at conduit replacement.
TABLE 2. Incidence of homograft conduit stenosis by
subgroup
Conduit contracture or shrinkage 21 (53%)
Technical issues 12 (30%)
Distal anastomotic stenosis 4
Conduit kinking 3
Sternal compression 3
Posterior shelf impingement 2
Multiple levels of stenosis 7 (17%)
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Discussion
Although cryopreserved allografts are generally considered
to be the best valved conduits for reconstruction of the
RVOT, their durability is far from ideal. A number of
studies have documented the actuarial freedom from ho-
mograft valve failure.1-8 In general, the failure rate is about
40% at 10 years. These same reports have documented both
univariant and multivariant risk factors for homograft fail-
ure. The most consistent multivariant risk factors include
smaller homograft diameter, younger recipient age, and
weight. Additionally, aortic homografts have been found to
fail more rapidly than conduits of pulmonary origin.2,4,5,7,8
Anatomic substrate has also been correlated with homograft
longevity with truncus arteriosus, transposition, and double-
outlet right ventricle associated with earlier failure.1,7
It has been assumed that homograft failure in younger
recipients is often due to somatic outgrowth. The findings in
this study suggest that although this occurs, it is unusual. At
the time of replacement, most homograft valves have a
diameter that should not be obstructive. Previous reports
have attempted to categorize the causes of homograft fail-
ure. Sano and colleagues,19 in 1991, detailed the indications
for conduit replacement and the sites of conduit obstruction
in 43 patients. These were described as extracardiac con-
duits, and conduit obstruction at the valvular level was cited
as the most common indication. Bando and coworkers8 also
reported on the indications for homograft replacement in 42
patients. In this series homograft stenosis was the primary
indication for reoperation in 69% of patients.
Among the 40 failed homografts in this series, stenosis
caused by contracture was the most common indication for
reoperation. The cause of this contracture is not exactly
known, but there is increasing evidence that the immune
system may be playing a major role. Early work by Cochran
and Kunzelman9 demonstrated that cryopreservation does
not alter antigenic expression of allografts. The cellular
viability, which was believed to be so important for cryo-
preserved homograft valve durability, may well provide the
antigenicity that leads to graft destruction. Preservation of
endothelial and valve architecture suggests that it is an
immunologic reaction rather than the cryopreservation pro-
cess itself that is responsible for the degenerative process.10
Extensive work has been carried out demonstrating the
role of the humoral immune response after implantation of
cryopreserved allografts into pediatric patients.11-14
Hawkins and colleagues11 have shown that cryopreserved
allograft tissue induces a marked response that involves
both class I and class II anti-HLA antibodies within 3
months. These HLA antibodies have been shown to persist
for more than a year after the operation.12
Cell-mediated immune response has also been shown in
the degeneration of cryopreserved homografts.15-18 Ranjani
and colleagues15 found that among 5 children with failed
homografts, all had inflammation consisting of T and B
lymphocytes in their explanted tissue. Work on a sheep
model demonstrated that lymphocytes are present in cryo-
preserved homografts up to 12 months after implantation.10
In addition, lymphocyte cultures have been propagated in an
interleukin 2–conditioned medium from explanted ho-
mografts,16 and recent experimental work has shown that
allograft heart valves in the rat model undergo T cell–
mediated immune rejection, resulting in structural failure.17
Both animal models and human studies have demon-
strated histopathologic evidence consistent with rejection
within explanted cryopreserved homografts. Using a rat
model, Motomura and colleagues18 were able to show that
after allotransplantation of cryopreserved rat aorta, intimal
thickening, medial necrosis, and cellular infiltration in the
adventitia (all manifestations of rejection) were present.18 In
a study by Ranjani and coworkers,15 5 homograft valves
explanted from infants with rapid conduit failure showed
lymphocytic infiltration within the valve leaflets and aortic
sleeves consistent with rejection. These findings have lead
to the consideration of the use of immune suppression for
patients undergoing homograft implantation. A report pro-
spectively evaluating the use of azathioprine on the humoral
immune response and homograft function in children re-
ceiving valved allografts found no significant decrease in
immune response to HLA antibodies or in the function of
the cryopreserved valves in the treated versus the control
group.20
Homograft insufficiency was the primary indication for
conduit replacement in only one patient but was universally
present. In fact, insufficiency is probably an important con-
tributing factor to conduit failure because the additional
volume load that comes with valve regurgitation heightens
the gradient across a stenotic conduit. Therefore, preserva-
tion of valve structural integrity is important in prolonging
homograft durability.
Although intrinsic contracture was the most common
cause for homograft stenosis in this series, anatomic distor-
tion may also play a significant role. Sternal compression
may lead to homograft valve annular distortion. Turbulence
created by this distortion may be partially responsible for
valve deterioration with loss of function. The nearly uni-
versal finding of valve insufficiency associated with the
aging of homograft conduits suggests the likely high inci-
dence of this distortion problem. It has been our experience
that marked oversizing of conduits, particularly in infants,
may be counterproductive because conduit distortion may
lead to more rapid deterioration than if a smaller size had
been chosen. In addition, certain anatomic variants seem to
predispose to conduit compression and more rapid failure.
An example from this series is L-TGA with pulmonary
stenosis or atresia requiring conduit reconstruction. Because
the conduit must be positioned to the right of the aorta, it by
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necessity lies immediately beneath the sternum. One of our
patients experienced 2 conduit failures after the usual ho-
mograft routing for L-TGA with pulmonary atresia. The
patient also had a relatively narrow anterior-posterior chest
diameter. This patient eventually had conduit replacement
with rerouting to bring the conduit from the apex of the
pulmonic ventricle and then following a curving course
along the right heart back up to the inferior aspect of the
right pulmonary artery successfully, avoiding the sternal
compression problem.
A potential solution to the problem of conduit distortion
could be to reinforce the homograft anulus with a rigid ring.
It might be helpful to have such support both at the anulus
and sinotubular junction to ensure optimal leaflet alignment.
Another potentially important technical issue involves
the positioning of the proximal conduit anastomosis. If the
homograft is sewn posteriorly to the epicardial aspect of the
ventriculotomy, it tends to sit much higher (extracardiac). A
hood is then needed to provide a smooth outflow tunnel.
This extracardiac positioning would seem to be more sus-
ceptible to compression and homograft distortion. The al-
ternative is to bring the proximal anastomosis down into the
RVOT, sewing the posterior anastomotic suture line to the
infundibular septum. In this case the anterior aspect of the
connection can usually be sewn primarily to the ventricu-
lotomy. This in situ or orthotopic positioning has a lower
profile but may distort the homograft annular region by
posterior muscle impingement posteriorly, which indents
the homograft as the conduit emerges from the RVOT over
a muscle shelf.
We propose that the optimal model for judging ho-
mograft durability comes when conduits are placed during
the Ross procedure. Because the pulmonary tree is undis-
torted and the homograft can be trimmed to fit precisely into
the autograft bed, this anatomic subtype should give us the
best information about intrinsic homograft durability. Early
results from our Ross experience and that of others6 sug-
gests improved durability of homografts in these patients
compared with in other anatomic subtypes.
The ideal conduit is one that would posses both excellent
long-term durability and the potential for growth. Engineer-
ing of a valved conduit made from a patient’s own cells may
offer these properties. Early experience with tissue engi-
neering has been encouraging.21,22 Goldstein and col-
leagues21 recently reported their work on a bioengineered
xeno-autograft. A composite valve made from decellular-
ized porcine aortic leaflets was implanted into a weanling
sheep. After several months, the valves were found to have
recellularized, and the short-term function was good. Other
centers are working on a biodegradable and biocompatible
scaffold that can be seeded with a patient’s own vascular
cells in vitro and subsequently implanted. Using a lamb
model with a scaffold made out of polyhydroxyalkanoates,
reasonable function of trileaflet heart valves has been ob-
served for up to 120 days.22 Although work with engineered
autografts is very new, these early results are promising.
Meanwhile, further work to investigate the mechanisms of
cryopreserved homograft failure, specifically establishing a
clearer role of the immune system in homograft degenera-
tion, is warranted.
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Discussion
Dr John W. Brown (Indianapolis, Ind). I agree with most of
your conclusions. I do have a couple of comments.
First, pulmonary homografts have been pretty disappointing,
both in our hands and in yours.
Second, in your service 50% of the pulmonary homografts had
shrunk to half their size within 5 years. When you went back to
reoperate on them, you put in a second pulmonary homograft.
Why? Is that all you had to use? Did you consider other tech-
niques? A simple patch or a monocusp patch might be better than
putting a second pulmonary homograft in the patient when that
first one failed within 5 years.
Third, when you reoperated on these patients for their second
conduit, you exposed the femoral vessels on 39 of the 40 patients.
Have you not used the polytetrafluoroethylene membrane to cover
the right heart and conduit when you do your initial correction? I
know that we have used the polytetrafluoroethylene pericardial
membrane in more than 500 patients now. I have not encountered
a problem with it, and its presence allows me to relax a lot more
when the resident is using the oscillating sternal saw for the redo
sternotomy.
I enjoyed your beautiful presentation. I agree with your results.
I, too, am disappointed with pulmonary homografts.
I have one further question. Did you measure panel-reactive
antibodies in your patients to see whether they had an immune
reaction to these initial homografts? Did you speculate some sort
of a mechanical factor with turbulence causing these homografts to
deteriorate more quickly than would have anticipated?
Dr Wells. Thank you, John. I will take your points in reverse
order.
We did not measure panel-reactive antibodies. There are an
increasing number of studies coming out looking at this, particu-
larly as some of the newer ideas in how to reduce the immunoge-
nicity of homografts are coming forward.
On the second point you made, actually we had 3 patients in
whom we had to cannulate the femoral vessels because of an
adventurous sternal opening.
We do not routinely use membranes unless we think the con-
duit is going to be up near the sternum, in which case we do. But
we did have 3 of the 40 patients in whom we had to cannulate the
femoral artery; otherwise, they were all standard cannulations.
Finally, why do we keep using homografts? I guess one way to
answer would be that we do not know what is better yet. There
may be some things on the horizon that could be better. The idea
that we should be preserving the cellularity of homografts to make
them viable may have been completely wrong. Maybe the better
thing to do is have no living cells in these homograft conduits and
let the patient repopulate them. We are quite interested in that
concept and think it may be better.
We have, more recently, since we put together this series,
implanted some stented xenograft bioprostheses into patients, par-
ticularly larger patients in whom we are doing a homograft re-
placement, believing that there is some evidence that they may
actually be more durable than the homografts themselves. I know
there are some other new ideas, John, including the bovine con-
duits that are under investigation, and we are very interested in the
outcomes of those sorts of conduits. Almost anything might be
better than what we have.
Dr John E. Mayer (Boston, Mass). I would like to offer one
other hypothesis for your consideration. Given the fact that the
homografts probably do not grow in length, if the right ventricu-
lotomy to pulmonary artery bifurcation distance increases, then
one has the famous Chinese finger puzzle phenomenon. My im-
pression is that this not infrequently causes the homograft diameter
to narrow as it is asked to elongate. I wondered what your thoughts
might be about that and whether that does not explain at least some
of the diffuse narrowing that occurs throughout the length of some
of the homografts.
Dr Wells. Thank you, John. I do not know that you are wrong.
I suspect that as that lengthening process goes on, the native
vessels would be more likely to be compliant and come toward the
homograft, but I cannot disprove your theory.
Dr Brown. Twenty of your 40 patients had tetralogy or tetralogy
complex. I know at our institution we almost never use a conduit
for tetralogy. Is there a different kind of tetralogy in Los Angeles?
Even in the children with acquired pulmonary atresia, you can
bring the proximal main pulmonary artery down to the RVOT and
then either roof it over with a simple patch or, as we do, put a
monocusp in and then roof it over with a patch. It sounds like you
are throwing away the native back wall of the RVOT when you
inset a conduit in tetralogy and its variants. Why?
Dr Wells. For most of these tetralogies, John, I think it is a
question of terminology. These are really tetralogy of Fallot/
pulmonary atresia, ventricular septal defect/pulmonary atresia,
whatever you want to call them. There is more of those variants
than there are just hypoplastic anuli. It is a question of terminology
more than anything else.
Dr Francois Lacour-Gayet (Hamburg, Germany). I totally
agree with you that the patients do not outgrow their homografts.
Finally, you define in this way a sort of outgrowth age or
outgrowth time. Can you try to assign a number to that? For
example, how much time must pass after a conduit is placed in a
neonatal repair of truncus arteriosus before it is acceptable to say
that the patient has outgrown the valved conduit?
My second point is that, contrary to your experience, we have
observed severe insufficiency with homografts, especially in trun-
cus. Personally, I have seen total disappearance of the leaflets of
the homograft several times. Have you seen this and do you
suspect an immunologic process.
Dr Wells. Thank you for your comments. I will take the last
one first.
I hope I did include in my remarks the fact that most of these
homografts had a good deal of insufficiency, some moderate and
some severe. I would agree, when you look at these contracture-
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shrinkage patients, you cannot find the leaflets. It has all become
fibrosed. One of the things that is hard to do is to determine the
histologic features, because by the time you go back, it is at the end
stage of the process, and it is all just fibrosed and gone.
I agree with you that insufficiency is playing a role here.
Usually it is a gradient that is driving the patient back to you for
homograft replacement. The cardiologist is sending him back
saying there is stenosis here, and it is rarely just pure insufficiency.
At least that is our experience.
Finally, with regard to outgrowing the homograft: Usually
when these homografts are implanted, they are at least 2 to 3 and
sometimes 5 SDs larger than what is appropriate for the patient’s
weight. After this destruction has taken place, the patient still has
a big enough anulus if the homograft has not been affected by this
process. That is what I meant by “outgrow.” I mean they have a big
enough anulus; it is just that the anulus is contracted or shrunken.
This is usually about a 5- to 7-year process on the basis of this
experience.
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